AFT Pharmaceuticals Limited logo

AFT appoints Allison Yorston as independent director

Director Appointment12 November 2024AFTHealthcare

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:

ARBN 609 017 969 investor.relations@aftpharm.com






12 November 2024

AFT appoints Allison Yorston as independent

director

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces the appointment of

Allison Yorston as an independent non-executive director.

The appointment fills the vacancy left by Anita Baldauf who retired from the board at

the shareholders meeting in August.

Chair David Flacks says: “We are delighted to welcome Allison to our board. She has

outstanding experience as a senior marketing executive in Australia and New Zealand

and is currently the Chief Marketing Officer for Suntory Beverage and Food Oceania.

“Allison’s senior marketing experience is highly relevant to AFT as we grow and

consolidate our position in Australasia and build our presence internationally with our

Maxigesic® pain relief and other medications.”

Allison says: “I am excited by the opportunity to assist AFT with its growth aspirations

and honoured to join the experienced board. I look forward to utilising my strategic,

commercial and marketing skillset for positive impact.”

The board has determined that Allison Yorston is an Independent Director (within the

meaning of the NZX Listing Rules).


For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial

Officer.


For more information:

Investors Media

Dr Hartley Atkinson Richard Inder

Managing Director The Project

AFT Pharmaceuticals Tel: +64 21 645 643

Tel: +64 9488 0232


About AFT Pharmaceuticals

AFT is a growing New Zealand based multinational pharmaceutical company that

develops, markets, and distributes a broad portfolio of pharmaceutical products

across a wide range of therapeutic categories which are distributed across all major

pharmaceutical distribution channels: over the counter (OTC), prescription and

hospital. Our product portfolio comprises both proprietary and in-licensed products,

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:

ARBN 609 017 969 investor.relations@aftpharm.com


and includes patented, branded, and generic drugs

1

. Our business model is to

develop and in-license products for in our markets of Australia, New Zealand,

Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-

license our products to local licensees and distributors to over 125 countries around

the world. For more information about the company, visit our website

www.aftpharm.com.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.